Hard to see what is really going to move the SP (up) with the half year numbers. I guess with dose sales at the upper end of the forecast (5.6%) we should expect EBITDA should be as well - $32m? I can't see SRX pulling a rabbit out of the hat here - even xrates are going against us. Maybe some clarification on dates re announcements on trials but overall I think I will be happy if the SP stays where it is. Anyway one more sleep to go.
Hard to see what is really going to move the SP (up) with the...
Add to My Watchlist
What is My Watchlist?